Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina

Alejandro E. Macías Hernández; Fortino Solórzano Santos; Hugo M. Aguilar Velasco; María L. Ávila Agüero; Fernando Bazzino Rubio; Nancy C. Junqueira Bellei; Pablo E. Bonvehí; José Brea Del Castillo; Héctor Castro Leguizamón; Carla M. Allan Santos Domingues; María D.L. García García; Darío Londoño Trujillo; Pío López Lópe; Samuel Ponce De León Rosales; Patricia G. Cervantes Powell; Luis A.N. Suárez Ognio; Guillermo M. Ruiz-Palacios y Santos

Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina

Translated title of the contribution: Influenza tetravalent vaccines in national immunization programs for Latin-American countries

Alejandro E. Macías Hernández
, Fortino Solórzano Santos
, Hugo M. Aguilar Velasco
, María L. Ávila Agüero
, Fernando Bazzino Rubio
, Nancy C. Junqueira Bellei
, Pablo E. Bonvehí
, José Brea Del Castillo
, Héctor Castro Leguizamón
, Carla M. Allan Santos Domingues
, María D.L. García García
, Darío Londoño Trujillo
, Pío López Lópe
, Samuel Ponce De León Rosales
, Patricia G. Cervantes Powell
, Luis A.N. Suárez Ognio
, Guillermo M. Ruiz-Palacios y Santos

Universidad de Guanajuato
Caja Costarricense de Seguro Social
Hospital Infantil de Mexico Federico Gomez
Universidad Central del Ecuador
Hospital Británico
Universidade Federal de São Paulo
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
Santo Domingo Institute of Technology
Universidad Nacional de Asunción
Ministério da Saúde do Brasil
Instituto Nacional de Salud Publica
Fundación Santa Fe de Bogotá
Hospital Universitario del Valle (Univalle)
Universidad Nacional Autónoma de México
Sanofi-Aventis
nstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (incmsz)

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.

Translated title of the contribution	Influenza tetravalent vaccines in national immunization programs for Latin-American countries
Original language	Spanish
Pages (from-to)	92-99
Number of pages	8
Journal	Enfermedades Infecciosas y Microbiologia
Volume	40
Issue number	3
State	Published - Jul 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Macías Hernández, A. E., Santos, F. S., Aguilar Velasco, H. M., Ávila Agüero, M. L., Rubio, F. B., Junqueira Bellei, N. C., Bonvehí, P. E., Del Castillo, J. B., Leguizamón, H. C., Allan Santos Domingues, C. M., García García, M. D. L., Trujillo, D. L., Lópe, P. L., De León Rosales, S. P., Cervantes Powell, P. G., Suárez Ognio, L. A. N., & Ruiz-Palacios y Santos, G. M. (2020). Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina. Enfermedades Infecciosas y Microbiologia, 40(3), 92-99.

@article{47de345f7fec4d678f936bab64173fe6,

title = "Vacuna tetravalente de influenza en los programas nacionales de inmunizaci{\'o}n para los pa{\'i}ses de Am{\'e}rica Latina",

abstract = "Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6\% of influenza cases and more than 50\% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32\% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4\%), or 2.65 (95\% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5\%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.",

keywords = "Influenza b, Latin America, Tetravalent influenza vaccine",

author = "\{Mac{\'i}as Hern{\'a}ndez\}, \{Alejandro E.\} and Santos, \{Fortino Sol{\'o}rzano\} and \{Aguilar Velasco\}, \{Hugo M.\} and \{{\'A}vila Ag{\"u}ero\}, \{Mar{\'i}a L.\} and Rubio, \{Fernando Bazzino\} and \{Junqueira Bellei\}, \{Nancy C.\} and Bonveh{\'i}, \{Pablo E.\} and \{Del Castillo\}, \{Jos{\'e} Brea\} and Leguizam{\'o}n, \{H{\'e}ctor Castro\} and \{Allan Santos Domingues\}, \{Carla M.\} and \{Garc{\'i}a Garc{\'i}a\}, \{Mar{\'i}a D.L.\} and Trujillo, \{Dar{\'i}o Londo{\~n}o\} and L{\'o}pe, \{P{\'i}o L{\'o}pez\} and \{De Le{\'o}n Rosales\}, \{Samuel Ponce\} and \{Cervantes Powell\}, \{Patricia G.\} and \{Su{\'a}rez Ognio\}, \{Luis A.N.\} and \{Ruiz-Palacios y Santos\}, \{Guillermo M.\}",

year = "2020",

month = jul,

language = "Espa{\~n}ol",

volume = "40",

pages = "92--99",

journal = "Enfermedades Infecciosas y Microbiologia",

issn = "1405-0994",

publisher = "Comunicaciones Cientificas Mexicanas S.A. de C.V.",

number = "3",

}

Macías Hernández, AE, Santos, FS, Aguilar Velasco, HM, Ávila Agüero, ML, Rubio, FB, Junqueira Bellei, NC, Bonvehí, PE, Del Castillo, JB, Leguizamón, HC, Allan Santos Domingues, CM, García García, MDL, Trujillo, DL, Lópe, PL, De León Rosales, SP, Cervantes Powell, PG, Suárez Ognio, LAN & Ruiz-Palacios y Santos, GM 2020, 'Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina', Enfermedades Infecciosas y Microbiologia, vol. 40, no. 3, pp. 92-99.

TY - JOUR

T1 - Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina

AU - Macías Hernández, Alejandro E.

AU - Santos, Fortino Solórzano

AU - Aguilar Velasco, Hugo M.

AU - Ávila Agüero, María L.

AU - Rubio, Fernando Bazzino

AU - Junqueira Bellei, Nancy C.

AU - Bonvehí, Pablo E.

AU - Del Castillo, José Brea

AU - Leguizamón, Héctor Castro

AU - Allan Santos Domingues, Carla M.

AU - García García, María D.L.

AU - Trujillo, Darío Londoño

AU - Lópe, Pío López

AU - De León Rosales, Samuel Ponce

AU - Cervantes Powell, Patricia G.

AU - Suárez Ognio, Luis A.N.

AU - Ruiz-Palacios y Santos, Guillermo M.

PY - 2020/7

Y1 - 2020/7

N2 - Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.

AB - Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.

KW - Influenza b

KW - Latin America

KW - Tetravalent influenza vaccine

UR - https://www.scopus.com/pages/publications/85096872537

M3 - Artículo

AN - SCOPUS:85096872537

SN - 1405-0994

VL - 40

SP - 92

EP - 99

JO - Enfermedades Infecciosas y Microbiologia

JF - Enfermedades Infecciosas y Microbiologia

IS - 3

ER -

Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this